Chae-Yong Kim1,2, Sun Ha Paek3, Do-Hyun Nam4, Jong-Hee Chang5, Yong-Kil Hong6, Jeong Hoon Kim7, Oh Lyong Kim8, Se-Hyuk Kim9. 1. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea. chaeyong@snu.ac.kr. 2. Neuro-Oncology Division of Department of Neurosurgery, SNU Bundang Comprehensive Cancer Hospital and Bundang Clinical Neuro-Science Institute, Seoul National University Bundang Hospital, Seongnam, South Korea. chaeyong@snu.ac.kr. 3. Department of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea. 4. Department of Neurosurgery, Sungkyunkwan University School of Medicine, Seoul, South Korea. 5. Department of Neurosurgery, Yonsei University Health System Severance Hospital, Seoul, South Korea. 6. Department of Neurosurgery, The Catholic University of Korea, Seoul, South Korea. 7. Department of Neurosurgery, Asan Medical Center, Seoul, South Korea. 8. Department of Neurosurgery, Yeungnam University Medical Center, Daegu, South Korea. 9. Department of Neurosurgery, Ajou University Hosptial, Suwon, South Korea.
Abstract
BACKGROUND: Tumor treating fields (TTFields) are anti-mitotic, non-invasive loco-regional cancer therapy comprising low intensity, intermediate frequency alternating electric fields. TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We report on Korean newly diagnosed GBM patients who participated in the EF-14 trial. METHODS: Thirty-nine participants of the EF-14 trial were enrolled at 8 sites in South Korea. Patients (24 TTFields/TMZ; 14 TMZ alone) received: TTFields (200 kHz) for > 18 h/day; TMZ at 120-150 mg for 5 days per a 28 day cycle. Safety and efficacy were assessed. RESULTS: Patient baseline characteristics were balanced in the 2 arms and the mean age was 52.1 years, 66.7% were male with a mean KPS of 90. Safety incidence was comparable between the 2 arms. In the TTFields/TMZ arm, 30% suffered from skin irritation versus 52% in the entire study population. No TTFields-related serious adverse events were reported. The median progression-free survival (PFS) in the TTFields/TMZ arm was 6.2 months (95% CI 4.2-12.2) versus 4.2 (95% CI 1.9-11.2) with TMZ alone (p = 0.67). Median overall survival was 27.2 months (95% CI 21-NA) with TTFields/TMZ versus 15.2 months (95% CI 7.5-24.1; HR 0.27, p = 0.01) with TMZ alone. CONCLUSION: Median OS and 1- and 2-year survival rates were higher with TTFields/TMZ and similar to the entire EF-14 population. About 30% of patients reported skin irritation, a lower rate than seen in the entire EF-14 population. These results demonstrate the efficacy and safety of TTFields in Korean newly diagnosed glioblastoma patients. CLINICAL TRIALS: Clinicaltrials.gov Identifier: NCT00916409.
BACKGROUND: Tumor treating fields (TTFields) are anti-mitotic, non-invasive loco-regional cancer therapy comprising low intensity, intermediate frequency alternating electric fields. TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We report on Korean newly diagnosed GBM patients who participated in the EF-14 trial. METHODS: Thirty-nine participants of the EF-14 trial were enrolled at 8 sites in South Korea. Patients (24 TTFields/TMZ; 14 TMZ alone) received: TTFields (200 kHz) for > 18 h/day; TMZ at 120-150 mg for 5 days per a 28 day cycle. Safety and efficacy were assessed. RESULTS: Patient baseline characteristics were balanced in the 2 arms and the mean age was 52.1 years, 66.7% were male with a mean KPS of 90. Safety incidence was comparable between the 2 arms. In the TTFields/TMZ arm, 30% suffered from skin irritation versus 52% in the entire study population. No TTFields-related serious adverse events were reported. The median progression-free survival (PFS) in the TTFields/TMZ arm was 6.2 months (95% CI 4.2-12.2) versus 4.2 (95% CI 1.9-11.2) with TMZ alone (p = 0.67). Median overall survival was 27.2 months (95% CI 21-NA) with TTFields/TMZ versus 15.2 months (95% CI 7.5-24.1; HR 0.27, p = 0.01) with TMZ alone. CONCLUSION: Median OS and 1- and 2-year survival rates were higher with TTFields/TMZ and similar to the entire EF-14 population. About 30% of patients reported skin irritation, a lower rate than seen in the entire EF-14 population. These results demonstrate the efficacy and safety of TTFields in Korean newly diagnosed glioblastoma patients. CLINICAL TRIALS: Clinicaltrials.gov Identifier: NCT00916409.
Entities:
Keywords:
Glioblastoma; Korean GBM patients; Tumor treating fields
Authors: Matthew Koshy; John L Villano; Therese A Dolecek; Andrew Howard; Usama Mahmood; Steven J Chmura; Ralph R Weichselbaum; Bridget J McCarthy Journal: J Neurooncol Date: 2011-10-09 Impact factor: 4.130
Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300
Authors: Nidhi Gera; Aaron Yang; Talia S Holtzman; Sze Xian Lee; Eric T Wong; Kenneth D Swanson Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Michael J Strong; Sravanthi Koduri; Jodi A Allison; Cecilia M Pesavento; Sebele Ogunsola; Oludotun Ogunsola; Timothy J Yee; Siri Sahib S Khalsa; Yamaan S Saadeh; Jacob R Joseph; Osama N Kashlan; Paul Park; Mark E Oppenlander; Nicholas J Szerlip Journal: J Neurooncol Date: 2022-05-17 Impact factor: 4.130
Authors: Michael Itak Ita; Jiang Huai Wang; André Toulouse; Chris Lim; Noel Fanning; Michael O'Sullivan; Yvonne Nolan; George Finbarr Kaar; Henry Paul Redmond Journal: Acta Neurochir (Wien) Date: 2021-10-13 Impact factor: 2.816